Recursion 将于 11 月 19 日在巴塞罗那 ENA Symposium 展示 REC-7735 的临床前数据。REC-7735 是 AI 精准设计的口服 PI3Kα H1047R 抑制剂,对 H1047R 的选择性超过野生型 100 倍,并在多种实体瘤体内模型中显示疗效。在 naïve 或糖尿病动物中,即使超有效剂量也未影响血糖、胰岛素等代谢指标。
We’ll be at this year’s EORTC-NCI-AACR (ENA) Symposium on Nov 19th in Barcelona.
Recursion’s Erik Müllers will be presenting on REC-7735: an AI precision-designed, oral PI3Kα H1047R inhibitor which targets a key oncogenic driver in multiple solid tumors, including breast, colorectal, endometrial, and ovarian cancers.
REC-7735 selectively targets PI3Kα H1047R while sparing wild-type, and offers the potential to overcome the limitations of current PI3Kα inhibitors.
Key preclinical findings highlighted in the poster include:
🔍 >100-fold selectivity for H1047R over wild-type PI3Kα.
🚀 Efficacy across multiple solid tumor models in vivo.
✅ In contrast to non-selective and moderately selective inhibitors, REC-7735 did not impact blood glucose, insulin levels, or other metabolic markers in naïve or diabetic animals, even at supra-efficacious doses.
Come check us out! For more information about REC-7735, see below:
https://cdn.prod.website-files.com/604197abb43603652c167bfa/6a7b2a579f45c05824cc4bb4_RXRX%20REC7735%202Q%2026%20(1).pdf
来源:Recursion · x.com